Improving immunization approaches to cholera

References

• Finkelstein RA. Cholera, vibrio cholerae O1 and O139, and other pathogenic vibrios. In: Baron S, Editor. Medical microbiology. Galveston TX: The University of Texas Medical Branch at Galveston; 1996.
   Google Scholar
• Schaetti C, Ali SM, Chaignat CL, et al. Improving community coverage of oral cholera mass vaccination campaigns: lessons learned in Zanzibar. Plos One. 2012;7(7):e41527.
   PubMed Web of Science ®Google Scholar
• WHO. Cholera vaccines position paper. Weekly Epidemiological Record (WER). 2010;85(13):117–128.
   Google Scholar
• Watson JT, Gayer M, Connolly MA. Epidemics after natural disasters. Emerg Infect Dis. 2007;13(1):1–5.
   PubMed Web of Science ®Google Scholar
• The Lancet ID. As cholera returns to Haiti, blame is unhelpful. Lancet Infect Dis. 2010;10(12):813.
   PubMed Web of Science ®Google Scholar
• Bharati K, Bhattacharya SK. Cholera outbreaks in South-East Asia. Curr Top Microbiol Immunol. 2014;379:87–116.
   PubMed Web of Science ®Google Scholar
• Mahapatra T, Mahapatra S, Babu GR, et al. Cholera outbreaks in South and Southeast Asia: descriptive analysis, 2003-2012. Jpn J Infect Dis. 2014;67(3):145–156.
   PubMed Web of Science ®Google Scholar
• Goel AK, Jain M, Kumar P, et al. Molecular characterization of vibrio cholerae outbreak strains with altered el tor biotype from southern India. World J Microbiol Biotechnol. 2010;26(2):281–287.
   PubMed Web of Science ®Google Scholar
• Ali M, Lopez AL, You YA, et al. The global burden of cholera. Bull World Health Organ. 2012;90(3):209–218A.
   PubMed Web of Science ®Google Scholar
• WHO. Cholera 2014. Weekly Epidemiological Record. 2015;40(90): 517–544.
   Google Scholar
• Lucas ME, Deen JL, Von Seidlein L, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med. 2005;352(8):757–767.
   PubMed Web of Science ®Google Scholar
• Khatib AM, Ali M, Von Seidlein L, et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. The Lancet Infectious Diseases. 2012;12(11):837–844.
   PubMed Web of Science ®Google Scholar
• Martin S, Lopez AL, Bellos A, et al. Post-licensure deployment of oral cholera vaccines: a systematic review. Bull World Health Organ. 2014;92(12):881–893.
   PubMed Web of Science ®Google Scholar
• Luquero FJ, Sack DA. Effectiveness of oral cholera vaccine in Haiti. The Lancet Global Health. 2015;3(3):e120–121.
   PubMed Web of Science ®Google Scholar
• Qadri F, Ali M, Chowdhury F, et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. The Lancet. 2015;386(10001):1362–1371.
   PubMed Web of Science ®Google Scholar
• Harris JB, LaRocque RC, Qadri F, et al. Cholera. Lancet (London, England). 2012;379(9835):2466–2476.
   PubMed Web of Science ®Google Scholar
• WHO. Cholera: mechanism for control and prevention (WHA64.15). World Health Organization 2011.
   Google Scholar
• Maponga BA, Chirundu D, Gombe NT, et al. Cholera:a comparison of the 2008-9 and 2010 outbreaks in Kadoma City. Zimbabwe Pan African Medical Journal. 2015;20:221.
   PubMed Web of Science ®Google Scholar
• Luquero FJ, Grout L, Ciglenecki I, et al. Use of vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med. 2014;370(22):2111–2120.
   PubMed Web of Science ®Google Scholar
• Von Seidlein L, Deen JL. Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010-2011. Emerg Infect Dis. 2012;18(7):1211–1214.
   PubMed Web of Science ®Google Scholar
• Kelvin AA. Outbreak of cholera in the Republic of Congo and the democratic Republic of Congo, and cholera worldwide. Journal Infection Developing 801 Countries. 2011;5(10):688–691.
   PubMed Web of Science ®Google Scholar
• The Lancet Infectious D. As cholera returns to Haiti, blame is unhelpful. The Lancet Infectious Diseases. 2010;10:(12).
   Web of Science ®Google Scholar
• Acosta CJ, Galindo CM, Kimario J, et al. Cholera outbreak in southern Tanzania: risk factors and patterns of transmission. Emerg Infect Dis. 2001;7(3 Suppl):583–587.
   Google Scholar
• Ali M, Nelson AR, Lopez AL, et al. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9(6):e0003832.
   PubMed Web of Science ®Google Scholar
• Farmer P, Almazor CP, Bahnsen ET, et al. Meeting cholera’s challenge to Haiti and the world: a joint statement on cholera prevention and care. PLoS Negl Trop Dis. 2011;5(5):e1145.
   PubMed Web of Science ®Google Scholar
• Kouadio IK, Aljunid S, Kamigaki T, et al. Infectious diseases following natural disasters: prevention and control measures. Expert Review of Anti Infective Therapy. 2012;10(1):95–104.
   PubMed Web of Science ®Google Scholar
• Bishop AL, Camilli A. Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev Vaccines. 2011;10(1):79–94.
   PubMed Web of Science ®Google Scholar
• Gaffga NH, Tauxe RV, Mintz ED. Cholera: a new homeland in Africa? Am J Trop Med Hyg. 2007;77(4):705–713.
   PubMed Web of Science ®Google Scholar
• Morris JG Jr. Cholera and other types of vibriosis: a story of human pandemics and oysters on the half shell. Clin Infect Dis. 2003;37(2):272–280.
   PubMed Web of Science ®Google Scholar
• Sack DA, Sack RB, Nair GB, et al. Cholera. Lancet (London, England). 2004;363(9404):223–233.
   PubMed Web of Science ®Google Scholar
• Lippi D, Gotuzzo E. The greatest steps towards the discovery of Vibrio cholerae. Clin Microbiology Infection. 2014;20(3):191–195.
   PubMed Web of Science ®Google Scholar
• Sinclair D, Abba K, Zaman K, et al. Oral vaccines for preventing cholera. Cochrane Database Syst Rev. 2011 Mar 16;(3): CD008603. doi:10.1002/14651858.CD008603.pub2.
   Google Scholar
• Crotty S, Ahmed R. Immunological memory in humans. Semin Immunol. 2004;16(3):197–203.
   PubMed Web of Science ®Google Scholar
• Butler SM, Camilli A. Going against the grain: chemotaxis and infection in Vibrio cholerae. Nat Rev Microbiol. 2005;3(8):611–620.
   PubMed Web of Science ®Google Scholar
• Qadri F, Wenneras C, Albert MJ, et al. Comparison of immune responses in patients infected with vibrio cholerae O139 and O1. Infect Immun. 1997;65(9):3571–3576.
   PubMed Web of Science ®Google Scholar
• Jertborn M, Svennerholm AM, Holmgren J. Saliva breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol. 1986;24(2):203–209.
   PubMed Web of Science ®Google Scholar
• Clemens JD, van Loon F, Sack DA, et al. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J Infect Dis. 1991;163(6):1235–1242.
   PubMed Web of Science ®Google Scholar
• Longini IM, Jr, Yunus M, Zaman K, et al. Epidemic and endemic cholera trends over a 33-year period in Bangladesh. J Infect Dis. 2002;186(2):246–251.
   Google Scholar
• Mahalanabis D, Faruque AS, Albert MJ, et al. An epidemic of cholera due to vibrio cholerae O139 in Dhaka, Bangladesh: clinical and epidemiological features. Epidemiol Infect. 1994;112(3):463–471.
   PubMed Web of Science ®Google Scholar
• Pasetti MF, Levine MM. Insights from natural infection-derived immunity to cholera instruct vaccine efforts. Clin Vaccine Immunol. 1707-1711;19(11):2012.
   Google Scholar
• WHO. Cholera Fact Sheet No. 107. WHO Media Centre, 2016.
   Google Scholar
• Ramakrishna BS, Venkataraman S, Srinivasan P, et al. Amylase-resistant starch plus oral rehydration solution for cholera. N Engl J Med. 2000;342(5):308–313.
   PubMed Web of Science ®Google Scholar
• WHO. Cholera, 2007. Weekly Epidemiological Record. 2008; 31(83):269–284.
   Google Scholar
• Santosham M, Chandran A, Fitzwater S, et al. Progress and barriers for the control of diarrhoeal disease. Lancet (London, England). 2010;376(9734):63–67.
   PubMed Web of Science ®Google Scholar
• Chaignat CL. What about cholera vaccines? Expert Rev Vaccines. 2008;7(4):403–405.
   PubMed Web of Science ®Google Scholar
• Mosley WH, Aziz KM, Rahman AS, et al. Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh–three years of observation. Bull World Health Organ. 1973;49(4):381–387.
   PubMed Web of Science ®Google Scholar
• Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries:lessons from a live cholera vaccine. BMC Biol. 2010;8:129.
   PubMed Web of Science ®Google Scholar
• Valneva. Vaccine against cholera and/or ETEC. 2015. Valneva products, 2015.
   Google Scholar
• Sanchez JL, Vasquez B, Begue RE, et al. Protective efficacy of oral wholecell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet (London, England). 1994;344(8932):1273–1276.
   PubMed Web of Science ®Google Scholar
• Desselberger U, Huppertz H-I. Immune responses to rotavirus infection and vaccination and associated correlates of protection. J Infect Dis. 2011;203(2):188–195.
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Sur D, Ali M, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebocontrolled trial. Lancet Infect Dis. 2013;13(12):1050–1056.
   PubMed Web of Science ®Google Scholar
• Chowdhury MI, Sheikh A, Qadri F. Development of Peru-15 (choleraGarde), a liveattenuated oral cholera vaccine: 1991-2009. Expert Rev Vaccines. 2009;8(12):16431652.
   Web of Science ®Google Scholar
• Chen WH, Greenberg RN, Pasetti MF, et al. Safety and immunogenicity of singledose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. Clin Vaccine Immunol. 2014;21(1):66–73.
   PubMed Web of Science ®Google Scholar
• Kanungo S, Sen B, Ramamurthy T, et al. Safety and immunogenicity of a live oral recombinant cholera vaccine VA1.4: a randomized, placebo controlled trial in healthy adults in a cholera endemic area in Kolkata, India. Plos One. 2014;9:(7), e99381.
   Google Scholar
• Baik YO, Choi SK, Olveda RM, et al. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines. Vaccine. 2015;33(46):6360–6365.
   PubMed Web of Science ®Google Scholar
• PaxVax. PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial. PaxVax Press Release, 2014.
   Google Scholar
• Anh DD, Lopez AL, Tran HT, et al. Oral cholera vaccine development and use in Vietnam. PLoS Med. 2014;11(9):e1001712.
   PubMed Web of Science ®Google Scholar
• Abubakar A, Azman AS, Rumunu J, et al. The first use of the global oral cholera vaccine emergency stockpile: lessons from South Sudan. PLoS Med. 2015;12(11):e1001901.
   PubMed Web of Science ®Google Scholar
• Sur D, Kanungo S, Sah B, et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis. 2011;5(10):e1289.
   PubMed Web of Science ®Google Scholar
• Mahalanabis D, Lopez AL, Sur D, . Placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. Plos One. 2008;3(6):e2323.
   PubMed Web of Science ®Google Scholar
• Saha A, Chowdhury MI, Khanam F, et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine. 2011;29(46):8285–8292.
   PubMed Web of Science ®Google Scholar
• Phares CR, Date K, Travers P, et al. Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand. Vaccine. 2016;34(1):128–133.
   PubMed Web of Science ®Google Scholar
• Ivers LC, Hilaire IJ, Teng JE, et al. Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis. The Lancet Global Health. 2015;3(3):e162–168.
   PubMed Web of Science ®Google Scholar
• Baik YO, Choi SK, Kim JW, et al. Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea. J Korean Med Sci. 2014;29(4):494501.
   Web of Science ®Google Scholar
• Incepta. Collaborative clinical trial for oral cholera vaccine launched in Bangladesh among incepta vaccine Ltd, IVI and icddr,b. Incepta vaccine Ltd, Bangladesh, 2016.
   Google Scholar
• Czerkinsky C, Holmgren J. Enteric vaccines for the developing world: a challenge for mucosal immunology. Mucosal Immunol. 2009;2(4):284–287.
   PubMed Web of Science ®Google Scholar
• Suharyono, Simanjuntak C, Witham N, et al. Safety and immunogenicity of singledose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet (London, England). 1992;340(8821):689–694.
   PubMed Web of Science ®Google Scholar
• Cryz SJ, Jr, Levine MM, Kaper JB, et al. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine. 1990;8(6):577–580.
   Google Scholar
• Tacket CO, Losonsky G, Nataro JP, et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103HgR. J Infect Dis. 1992;166(4):837–841.
   PubMed Web of Science ®Google Scholar
• Richie EE, Punjabi NH, Sidharta YY, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine. 2000;18(22):2399–2410.
   PubMed Web of Science ®Google Scholar
• PaxVax. FDA Approves Vaxchora, PaxVax’s Single-Dose Oral Cholera Vaccine. PaxVax Press Release, 2016.
   Google Scholar
• Kenner JR, Coster TS, Taylor DN, et al. Peru-15, an improved live attenuated oral vaccine candidate for vibrio cholerae O1. J Infect Dis. 1995;172(4):1126–1129.
   PubMed Web of Science ®Google Scholar
• Sack DA, Sack RB, Shimko J, et al. Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers. J Infect Dis. 1997;176(1):201–205.
   PubMed Web of Science ®Google Scholar
• Cohen MB, Giannella RA, Bean J, et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru15, a live attenuated oral cholera vaccine. Infect Immun. 2002;70(4):1965–1970.
   PubMed Web of Science ®Google Scholar
• Qadri F, Chowdhury MI, Faruque SM, et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine. 2007;25(2):231–238.
   PubMed Web of Science ®Google Scholar
• Qadri F, Chowdhury MI, Faruque SM, et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis. 2005;192(4):573–579.
   PubMed Web of Science ®Google Scholar
• Talavera A, Año G, García H, et al. Process development for a Cuban cholera vaccine based on the attenuated strain Vibrio cholerae. Vaccine. 2006;24(18):3746–3749.
   PubMed Web of Science ®Google Scholar
• Perry RT, Plowe CV, Koumaré B, et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ. 1998;76(1):63–71.
   PubMed Web of Science ®Google Scholar
• Mahalanabis D, Ramamurthy T, Nair GB, et al. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response. Vaccine. 2009;27(35):4850–4856.
   PubMed Web of Science ®Google Scholar
• Alam MM, Bufano MK, Xu P, et al. Evaluation in mice of a conjugate vaccine for cholera made from vibrio cholerae O1 (Ogawa) O-specific polysaccharide. PLoS Negl Trop Dis. 2014;8(2):e2683.
   PubMed Web of Science ®Google Scholar
• Sayeed MA, Bufano MK, Xu P, et al. A cholera conjugate vaccine containing ospecific polysaccharide (OSP) of V. cholerae O1 inaba and recombinant fragment of tetanus toxin heavy chain (OSP: rTTHc)induces serum, memory and lamina proprial responses against OSP and is protective in mice. PLoS Negl Trop Dis. 2015;9(7):e0003881.
   Web of Science ®Google Scholar
• Lanata CFMW, Black RE. Improving diarrhoea estimates. Geneva: World Health Organization; 2002.
   Google Scholar
• Tai SS. Streptococcus pneumoniae serotype distribution and pneumococcal conjugate vaccine serotype coverage among pediatric patients in East and Southeast Asia, 2000-2014: a pooled data analysis. Vaccines. 2016;4:1.
   Web of Science ®Google Scholar
• Karlsson SL, Ax E, Nygren E, et al. Development of stable vibrio cholerae o1hikojima type vaccine strains co–expressing the Inaba and Ogawa lipopolysaccharide antigens. Plos One. 2014;9(11):e108521.
   PubMed Web of Science ®Google Scholar
• Ali M, Sur D, You YA, et al. Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India. Clin Infect Dis. 2014;56(8):1123–1131.
   Web of Science ®Google Scholar
• Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in clinical trials. The Lancet Infectious Diseases. 2011;11(6):482–487.
   PubMed Web of Science ®Google Scholar
• Verma R, Khanna P, Chawla S. Cholera vaccine: new preventive tool for endemic countries. Hum Vaccin Immunother. 2012;8(5):682–684.
   PubMed Web of Science ®Google Scholar
• Koepke AA, Longini IM, Jr, Halloran ME, et al. Predictive modeling of cholera outbreaks in Bangladesh. Ann Appl Stat. 2016;10(2):575–595.
   Google Scholar
• Diekmann O, Heesterbeek JA, Metz JA. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. J Math Biol. 1990;28(4):365–382.
   Google Scholar
• Longini IM Jr., Nizam A, Ali M, et al. Controlling endemic cholera with oral vaccines. PLoS Med. 2007;4(11):e336.
   PubMed Web of Science ®Google Scholar
• Ali M, Emch M, Von Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet (London, England). 2005;366(9479):44–49.
   PubMed Web of Science ®Google Scholar
• Dimitrov DT, Troeger C, Halloran ME, et al. Comparative effectiveness of different strategies of oral cholera vaccination in bangladesh: a modeling study. PLoS Negl Trop Dis. 2014;8(12):e3343.
   PubMed Web of Science ®Google Scholar
• Saha A, Khan A, Salma U, et al. The oral cholera vaccine shanchol when stored at elevated temperatures maintains the safety and immunogenicity profile in 1003 Bangladeshi participants. Vaccine. 2016;34(13):1551–1558.
   PubMed Web of Science ®Google Scholar
• Kanungo S, Paisley A, Lopez AL, et al. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine. 2009;27(49):6887–6893.
   PubMed Web of Science ®Google Scholar
• Leach S, Lundgren A, Svennerholm AM. Different kinetics of circulating antibodysecreting cell responses after primary and booster oral immunizations: a tool for assessing immunological memory. Vaccine. 2013;31(30):3035–3038.
   PubMed Web of Science ®Google Scholar
• Qadri F, Wierzba TF, Ali M, et al. Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh. N Engl J Med. 1723-1732;374(18):2016.
   Google Scholar
• Kanungo S, Desai SN, Nandy RK, et al. Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone. PLoS Negl Trop Dis. 2015;9(3):e0003574.
   Web of Science ®Google Scholar
• Ciglenecki I, Sakoba K, Luquero FJ, et al. Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea. PLoS Med. 2013;10(9):e1001512.
   PubMed Web of Science ®Google Scholar
• Jeuland M, Cook J, Poulos C, et al. Cost-effectiveness of newgeneration oral cholera vaccines: a multisite analysis. Value Health. 2009;12(6):899–908.
   PubMed Web of Science ®Google Scholar
• Sarker AR, Islam Z, Khan IA, et al. Estimating the cost of cholera-vaccine delivery from the societal point of view: A case of introduction of cholera vaccine in Bangladesh. Vaccine. 2015;33(38):4916–4921.
   PubMed Web of Science ®Google Scholar
• Sarker AR, Islam Z, Khan IA, et al. Cost of illness for cholera in a high risk urban area in Bangladesh: an analysis from household perspective. BMC Infect Dis. 2013;13(1):1–6.
   PubMed Web of Science ®Google Scholar
• Naficy AB, Trach DD, Ke NT, et al. Cost of immunization with a locally produced, oral cholera vaccine in Vietnam. Vaccine. 2001;19(27):3720–3725.
   PubMed Web of Science ®Google Scholar
• Schaetti C, Weiss MG, Ali SM, et al. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar. PLoS Negl Trop Dis. 2012;6(10):e1844.
   PubMed Web of Science ®Google Scholar
• Martin S, Costa A, Perea W. Stockpiling oral cholera vaccine. Bull World Health Organ. 2012;90(10):714.
   PubMed Web of Science ®Google Scholar
• WHO. Cholera vaccines: WHO position paper-Recommendations. Vaccine. 2010;28(30):4687–4688.
   Google Scholar
• UNICEF. Guidance note on the use of Oral Cholera Vaccines for UNICEF. UNICEF, 2012.
   Google Scholar
• GAVI. Cholera vaccine supply and procurement roadmap. GAVI, The Vaccine Alliance, 2014.
   Google Scholar
• UNICEF. Oral Cholera Vaccine Market & Supply Update. UNICEF Supply Division, 2016.
   Google Scholar
• Desai SN, Pezzoli L, Martin S, et al. A second affordable oral cholera vaccine: implications for the global vaccine stockpile. The Lancet Global Health. 2016;4(4):e223224.
   Web of Science ®Google Scholar
• Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine. 2007;25(19):3752–3762.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and crossreactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet (London, England). 2007;370(9587):580–589.
   PubMed Web of Science ®Google Scholar
• McCullers JA, Dunn JD. Advances in vaccine technology and their impact on managed care. P & T: a Peer-Reviewed Journal for Formulary Management. 2008;33(1):3541.
   Google Scholar
• Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet (London, England). 2007;369(9580):2161–2170.
   PubMed Web of Science ®Google Scholar
• Bilukha O, Messonnier N, Fischer M. Use of meningococcal vaccines in the United States. Pediatr Infect Dis J. 2007;26(5):371–376.
   PubMed Web of Science ®Google Scholar
• Leach S, Clements JD, Kaim J, et al. The adjuvant double mutant escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens. Plos One. 2012;7(12):e51718.
   PubMed Web of Science ®Google Scholar
• Fletcher MA, Pneumococcal Conjugate FB. Vaccines and otitis media: an appraisal of the clinical trials. Int J Otolaryngol. 2012;312935:2012.
   Google Scholar
• BVGH. Polysaccharide protein conjugate vaccines. Bio Ventures for Global Health, 2015.
   Google Scholar
• Qadri F, Bhuiyan TR, Sack DA, et al. Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine. 2013;31(3):452–460.
   PubMed Web of Science ®Google Scholar
• Ahmed T, Svennerholm AM, Al Tarique A, et al. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine. 2009;27(9):1433–1439.
   PubMed Web of Science ®Google Scholar
• Qadri F, Ahmed T, Wahed MA, et al. Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccine. Vaccine. 2004;22(3–4):416–421.
   PubMed Web of Science ®Google Scholar
• Albert MJ, Qadri F, Wahed MA, et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J Infect Dis. 2003;187(6):909–913.
   PubMed Web of Science ®Google Scholar
• Harris JB, Podolsky MJ, Bhuiyan TR, et al. Immunologic responses to vibrio cholerae in patients co-infected with intestinal parasites in Bangladesh. PLoS Negl Trop Dis. 2009;3(3):e403.
   PubMed Web of Science ®Google Scholar
• Blum LS, Nahar N. Cultural and social context of dysentery: implications for the introduction of a new vaccine. J Health Popul Nutr. 2004;22(2):159–169.
   PubMed Web of Science ®Google Scholar
• Kaljee LM, Pack R, Pach A, et al. Sociobehavioural research methods for the introduction of vaccines in the diseases of the most impoverished programme. J Health Popul Nutr. 2004;22(3):293–303.
   PubMed Web of Science ®Google Scholar
• Streefland P, Chowdhury AM, Ramos-Jimenez P. Patterns of vaccination acceptance. Soc Sci Med. 1705-1716;49(12):1999.
   Google Scholar
• Streefland PH. Public doubts about vaccination safety and resistance against vaccination. Health Policy. 2001;55(3):159–172.
   PubMed Web of Science ®Google Scholar
• Emch M. Diarrheal disease risk in Matlab, Bangladesh. Soc Sci Med. 1999;49(4):519–530.
   PubMed Web of Science ®Google Scholar
• WHO. Initiative for Vaccine Research, Gender and Immunization-Summary report for SAGE. Swiss TPH, 2010.
   Google Scholar
• Caldwell J, McDonald P. Influence of maternal education on infant and child mortality: levels and causes. Health Policy Educ. 1982;2(3–4):251–267.
   PubMedGoogle Scholar
• Aibana O, Franke MF, Teng JE, et al. Cholera vaccination campaign contributes to improved knowledge regarding cholera and improved practice relevant to waterborne disease in rural Haiti. PLoS Negl Trop Dis. 2013;7(11):e2576.
   PubMed Web of Science ®Google Scholar
• Sundaram N, Schaetti C, Merten S, et al. Sociocultural determinants of anticipated oral cholera vaccine acceptance in three African settings: a meta-analytic approach. BMC Public Health. 2016;16(1):36.
   PubMed Web of Science ®Google Scholar
• Uddin MJ, Wahed T, Saha NC, et al. Coverage and acceptability of cholera vaccine among high-risk population of urban Dhaka, Bangladesh. Vaccine. 2014;32(43):5690–5695.
   PubMed Web of Science ®Google Scholar
• Wahed T, Kaukab SS, Saha NC, et al. Knowledge of, attitudes toward, and preventive practices relating to cholera and oral cholera vaccine among urban high-risk groups: findings of a cross-sectional study in Dhaka, Bangladesh. BMC Public Health. 2013;13:242.
   PubMed Web of Science ®Google Scholar
• Anh DD, Lopez AL, Thiem VD, et al. Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. PLoS Negl Trop Dis. 2011;5(1):e1006.
   PubMed Web of Science ®Google Scholar
• Andrews JR, Basu S. Transmission dynamics and control of cholera in Haiti: an epidemic model. Lancet (London, England). 2011;377(9773):1248–1255.
   PubMed Web of Science ®Google Scholar
• Reyburn R, Deen JL, Grais RF, et al. The case for reactive mass oral cholera vaccinations. PLoS Negl Trop Dis. 2011;5(1):e952.
   PubMed Web of Science ®Google Scholar
• WHO. Cholera vaccines: WHO position paper-recommendations. Vaccine. 2010;28(30):4687–4688.
   PubMed Web of Science ®Google Scholar